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Abstract
Objectives: Squamous cell carcinoma (SCC) is by far the most common malignant neoplasm of the oral cavity. A 
number of etiologic factors have been implicated in its development. During the past few decades, a particular focus 
has been placed on the investigation of valid biomarkers predictive of cancer behavior and cervical lymph node 
metastasis in head and neck Squamous cell carcinoma (HNSCC).The present study was designed to investigate the 
expression of epidermal growth factor in these tumors in relation to proliferation, apoptosis, angiogenesis and 
lymphangiogenesis.
Materials and methods: Immunohistochemical (IHC) evaluation of epidermal growth factor receptor (EGFR) 
expression in 40 retrospective OSCC specimens and its correlation with proliferating cell nuclear antigen (PCNA), 
antiapoptotic antibody (P53), vascular endothelial growth factor (VEGF), and D2-40 monoclonal antibodies (Mab), in 
relation to the clinicopathological parameters.
Results: Data revealed positive EGFR immunoreactivity in 35(87.5%) cases. There was a statistically significant 
correlation regarding EGFR extent score with respect to intratumoral lymphatic vessel density (ILVD) (r = 0.35) as well as 
EGFR intensity score with respect to ILVD and peritumoral lymphatic vessel density (PLVD) (r = 0.33, r = 0.36 
respectively). EGFR expression was not correlated with the clinicopathological parameters. Conclusions: EGFR is 
expressed by most of the cases. EGFR correlation with D2- 40 positive lymphatic vessels suggests a higher tendency of 
OSCC for lymphatic dissemination. Lack of correlation among the studied markers suggests their independent effect 
on tumor behavior.
Background
Oral squamous carcinogenesis is a multistep process in
which multiple genetic events occur that alter the normal
function of oncogenes and tumor suppressor genes (tsg).
Cancer related genes have to be considered in the context
of six fundamental changes [1].
•Self sufficiency in growth signals
•Insensitivity to growth inhibitory signals
•Evasion of apoptosis
•Limitless replicative potential
•Sustained angiogenesis
•Ability to invade and metastasize
All normal cells require stimulation on the basis of sig-
nals to undergo growth, differentiation and proliferation;
m a n y  o f  w h i c h  c a r r i e d  b y  g r o w t h  f a c t o r s  [ 1 , 2 ] .  E G F R
plays an important role in the differentiation and mor-
phogenesis of many organs and proliferation and survival
in mammalian cells [3,4]. EGFR has been reported to be
expressed in a variety of human tumors of epithelial ori-
gin; over expression of EGFR has been documented in
80% of SCC [1].
Angiogenesis is a crucial step in the successful growth,
invasion and metastasis of tumors, without which tumors
will not grow more than 1-2 mm3 in diameter [5,6]. VEGF
has been considered as a leading candidate in the process
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of tumor angiogenesis. Various studies reported upregu-
lation of VEGF in different malignancies [7,8].
Tissue growth depends on both cell proliferation and
the rate of cell death. PCNA is a 36 kd intra nuclear poly-
peptide protein whose expression is associated with DNA
synthesis and cell proliferation. Many studies demon-
strated an association of high expression rate of PCNA
with poor prognosis in solid tumors [2,9,10].
Apoptosis is a process of programmed cell death, it is as
essential as cell growth for the maintenance of homeosta-
sis [2,11]. P53 is a well known protein that regulates cell
cycle check points and is responsible for maintaining the
integrity of genome. Mutation of p53 tsg is one of the best
known and by far the most frequent genetic alteration
identified in malignant tumors [12].
Metastasis unequivocally signifies that a tumor is
malignant. Lymphangiogenesis which refers to the
growth of new lymphatic vessels has long been regarded
as a putative efficient pathway to neoplastic metastasiza-
tion [13,14]. A new selective immunohistochemical
marker is D2-40 which is specific for lymphatic endothe-
lium since it doesn't stain vascular endothelium.
Tumors vary considerably in their behavior, notably in
the rate of their growth, the degree of their differentiation
and the ability to invade and metastasize. Because of the
obscure and variable behavior of cancer, this study con-
cerned different aspects of tumor dynamics through the
immunohistochemcial evaluation of EGFR expression in
OSCC and its correlation with proliferation, apoptosis,
angiogenesis and lymphangiogensis via evaluating
PCNA, p53, VEGF and D2- 40 Mabs immunohistochem-
ically.
Methods
The study sample consisted of 40 retrospective OSCC
specimens from the department of oral pathology, college
of Dentistry, Baghdad University. An immunoshitochem-
cial staining with five types of Mabs was preformed: anti
EGFR & VEGF (Dako Cytomation -Denmark), anti
PCNA, anti P53 and anti D2-40 lymphatic endothelial
marker (Dako Cytomation - USA). Negative and positive
control slides were included in each IHC run (as recom-
mended by the manufacturers).
Immunohistochemistry staining procedure
All tests were carried out on 5 μm formalin fixed paraffin
embedded sections. Slides were baked in hot air oven at
65°C overnight. Sections were sequentially dewaxed
through a series of xylene, graded alcohol and water
immersion steps. Antigen (Ag) retrieving was done as
recommended by the manufacturers using 500 mL of cit-
rate buffer solution pH.6.0 for p53, pH 8.0 for VEGF and
D2-40, on a hot plate at temperature of (95-99°C), while
this step was omitted for PCNA Ag. Whereas EGFR Ag
and target retrieval was performed by pretreating tissue
sections using proteinase K proteolytic enzyme for 10
m i n u t e s .  T h e n  e n d o g e n o u s  p e r o x i d a s e  a c t i v i t y  w a s
blocked followed by blocking the non- specific staining.
Primary Abs (100 ml) was applied for each section. A
dilution of 1:25 for both EGFR and VEGF was used; 1:100
for D2-40, while PCNA and p53 Mabs were ready to
use.The samples were then incubated at 4°C overnight in
a humid chamber. After washing with PBS, secondary
Abs were applied to the sections, incubated and rinsed
with a stream of PBS. Primary Abs was visualized with
DAB chromogen. Sections were counterstained with
Mayer's hematoxyline for 30 seconds, dehydrated and
mounted.
Assessment of IHC results
In each tissue section five representative fields were
selected for EGFR, VEGF, PCNA and p53 Mabs and D2-
40 positive tumor cells with an average of 1000 tumor cell
per case and 200 tumor cells per field.
The immunoreactivity in tumor cells were classified
and scored as follows: -(0-25%), + (26-50%), ++ (51-75%),
+++(76-100%) for both PCNA and p53 [15]. ± (0-19%), +
(20-39%), ++ (40-59%), +++ (60-100%) for VEGF [16].
The extent of EGFR immunostaining was graded and
scored as follows: 0 points for negative staining of the
considered cells, (1) <10%, (2)10-50%, (3)51-80% and (4)
≥ 80% positive staining of the considered cells. The inten-
sity of staining was scored as 0, no staining; 1, weak; 2,
moderate; 3, strong [4,17] -< (10%), +(10-25%), ++(26-
50%), +++(51-100%) for D2-40 positive tumor cells [18].
D2-40 positivity was evaluated by selecting six "hot
spots" intratumorally and peritumorally. Lymphatic vessel
density (LVD) was expressed as the number of stained
vessels per optical field [18]. The average number of posi-
tively stained vessels in each region was evaluated and
recorded separately as intratumoral and peritumoral lym-
phatic vessel density (ILVD and PLVD). The average
count of positive vessels of both regions was recorded
together representing the total LVD (TLVD) for each
case. In addition, intratumoral (It) and peritumoral (Pt)
lymphatic vessel invasion (LVI) was considered evident if
at least one tumor cell cluster was clearly visible inside a
D2-40 positive vessel [18,19].
Mann-whitney test was used to explore the statistical
difference in median between two study groups. The sta-
tistical significance, direction and strength of linear cor-
r e l a t i o n  w e r e  m e a s u r e d  b y  s p e a r m a n ' s  r a n k  l i n e a r
correlation coefficient. P value less than the 0.05 level of
significance was considered statistically significant.Sarkis et al. Head & Neck Oncology 2010, 2:13
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Results
Clinicopathological data
The study sample consisted of 27 males (67.5%) and 13
females (32.5%) with an age range (24-86) years. Clini-
cally, ulcer represented the most frequent clinical presen-
tation (50%) of the cases. The majority of the cases (45%)
were seen in the tongue. T1 and T2 were presented in
12(31.6%) cases for each. Only 12 cases (30.8%) were
node positive. Most of the cases (43.2%) were TNM stage
III, and were histologically moderately differentiated car-
cinoma (50%).
Evaluation of IHC results
The positivity rate of the selected immunostains EGFR
(Fig.1), VEGF (Fig.2), PCNA (Fig.3), P53 (Fig.4); D2-40 in
the total sample is shown in (table 1) which reveals posi-
tive immunostaining in most of the cases.
Assessment of EGFR expression
Thirty five cases (87.5%) showed positive brown mem-
branous and/or cytoplasmic EGFR immunostaining. In
OSCC specimens the expression involved all the epithe-
lial layers while in normal oral mucosa it was localized to
the basal cell layer . EGFR positive cells were often seen
localized at the periphery of tumor nests. Besides EGFR
extent score, the intensity score was also considered. Rel-
ative frequency distribution revealed that (37.5%) of the
cases showed low intensity (35%) moderate and only
(15%) showed high intensity.
Assessment of D2-40 immunostainnig
D2-40 brown staining of lymphatic endothelial cells was
observed intratumorally, peritumorally or both. Positive
lymphatic vessels were unevenly distributed throughout
the tumor and their number in the (Pt) area was slightly
higher 34(85%) than that in the (It) area 28(70%).The total
lymphatic vessel stain was seen in 35 (87.5%) cases. The
D2-40 stained lymphatic vessels, the adjacent blood ves-
sels were always unstained (Fig.5).
Moreover, cancer cells were occasionally observed in
(It) lymphatic vessels and/or (Pt) lymphatic vessels
(Fig.6), LVI was detected in 13 (37.1%) cases out of 35 D2-
40 positive cases of which only five cases presented nodal
metastasis, eleven cases were grade II, one of the remain-
ing two was grade I and the other was grade III.
There was diffuse or strong granular cytoplasmic and/
or membranous D2-40 expression in the malignant epi-
thelial cells of 15 (37.5%) cases out of 35 D2-40 positive
cases the remaining 28 cases were totally devoid of stain-
ing. Eleven of the positive cases were grade II and the
remaining four were grade I. In addition, 7 of D2-40 posi-
tive tumor cell cases presented LVI. Furthermore, careful
examination of D2-40 expressing sections under oil
immersion revealed microinvasion of positive malignant
cells into the stromal tissue (Fig.7)
Figure 1 Positive brown membranous and or cytoplasmic EGFR 
immunostaining in well differentiated SCC (buccal mucosa, 
tongue and floor of mouth) (x100)
Figure 2 Strong granular cytoplasmic VEGF immunostaining in 
moderately differentiated SCC (x200)
Figure 3 Strong PCNA nuclear immunostaining in moderately 
differentiated SCC (tongue and floor of mouth (x200)Sarkis et al. Head & Neck Oncology 2010, 2:13
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Assessment of the biological markers in relation to the 
clinicopathological parameters as well as to each other
Mann-whitny's test showed a statistically non significant
difference regarding tumor stage, size, lymph node
metastasis and grade with the median expression of all
the study markers. The only exception was a highly sig-
nificant PLVD as well as a statistically significant TLVD
differences were found with respect to tumor grade (p =
0.002, p = 0.028) respectively (table 2). Moreover a highly
significant ILVD and TLVD and a statistically significant
PLVD difference was found with respect to LVI (p =
0.002, p = 0.004, p = 0.026) respectively (table 3).
On the other hand, spearman's rank linear correlation
coefficient test revealed a statistically significant correla-
tion in PCNA vs p53 (r = 0.34), EGFR extent score vs
ILVD (p = 0.35), EGFR intensity score vs ILVD, PLVD and
TLVD (p = 0.33, p = 0.36, p = 0.36) respectively. In addi-
tion D2-40 positive tumor cells showed a statistically sig-
nificant correlation vs ILVD and TLVD (p = 0.39, p =
0.32) respectively, ILVD vs PLVD and TLVD (p = 0.62, p =
0.85) respectively, PLVD vs TLVD and tumor grading (p =
0.92, p = 0.43) respectively (p < 0.05) (Table 4).
Discussion
It has been reported that the majority of head and neck
cancer, including oral cancer express EGFR [20]. Since
most oral cancers are epithelial in origin, it is reasonable
Figure 4 Strong P53 nuclear immunostaining localized to the 
cells surrounding tumor nests (moderately differentiated SCC-
tongue) (x200)
Table 1: The positivity rate of selected immunostains in the 
total sample
Positive immunostain (n = 40) No %
EGFR immunostain 35 87.5
VEGF immunostain 35 87.5
PCNA immunostain 34 85
P53 immunostain 21 52.5
D2-40 immunostain for tumor cells 15 37.5
Peritumoral LV stain 34 85
Intratumoral LV stain 28 70
Total LV stain 35 87.5
LV= Lymphatic vessel
Figure 5 D2-40 positive lymphatic vessels. The adjacent blood ves-
sel is negative (arrow) (moderately differentiated SCC-tongue) (x200)
Figure 6 D2-40 positive intratumoral lymphatic vessel contain-
ing tumor emboli (poorly differentiated SCC-buccal mucosa) 
(×200)Sarkis et al. Head & Neck Oncology 2010, 2:13
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that they should have a high probability of expressing
EGFR. In this series most of the examined cases (87.5%)
showed positive EGFR immunostaining. This finding is
consistent with previous reports regarding the immunos-
taining and expression of EGFR in OSCC and other can-
cers [4,17,20].
A well controlled balance of cellular differentiation and
proliferation is necessary for the development and main-
tenance of normal epithelia throughout the body; since
OSCCs are epithelial malignancies, therefore, they should
have a high probability of expressing EGFR. The present
study confirms the observations of others that high EGFR
expression is present in OSCCs which suggests that an
uncontrolled growth may be mediated by abnormal
EGFR expression [21].
EGFR expression extent and intensity scores revealed
by most of the study cases suggest that EGFR expressing
carcinomas display pathological features of more aggres-
sion which may be attributable to the activation of differ-
ent signaling pathways that control diverse biological
processes [4,22].
EGFR expression involved all epithelial layers in OSCC
specimens while in normal oral epithelia it was localized
to the basal cell layer, similar results were reported by
other investigators [20,23]. Since the squamous epithe-
lium keeps a continuous physiological regeneration in
normal conditions, so that it is reasonable that the basal
cells interpret signals of EGF by binding to EGFR [23],
while its expression beyond basal localization in cancer-
ous tissue suggests that a correlation between EGFR and
tumor progress may exist.
Figure 7 Strong D2-40 tumor cells immunostaining within the 
stromal tissue indicating single cell microinvasion (arrows) (mod-
erately differentiated SCC- mandible) (x1000)
Table 2: The difference in median score of selected 
immunostains by tumor grading (Mann-Whitney)
Tumor grading
Grade I Grade II-III P
Intratumoral LVD 0.24[NS]
Range (0 - 200) (0 - 160)
Median 18 30
Interquartile range (0 - 38) (8 - 57)
N1 7 2 3
Mean rank 18 22.35
Peritumoral LVD 0.004
Range (0 - 155) (0 - 240)
Median 15 60
Interquartile range (0 - 48) (35 - 100)
N1 7 2 3
Mean rank 14.29 25.09
Total LVD 0.028
Range (0 - 250) (0 - 300)
Median 46 93
Interquartile range (1 - 78) (48 - 173)
N1 7 2 3
Mean rank 15.79 23.98
LVD = lymphatic vessel densitySarkis et al. Head & Neck Oncology 2010, 2:13
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The expression was mainly localized to the peripheries
o f  t u m o r  n es ts,  t h is  o bs e rva t i o n  is  i n  a c c o r d a n c e  wi t h
other studies [20,23]. This finding confirms the presence
of this receptor on undifferentiated cells and explains that
the staining reaction varies with cellular differentiation.
Moreover, it may explain that peripheral tumor cells
receive a signal from EGF resulting in the proliferation of
cancerous tissues.
D2-40 positive lymphatic vessels were recorded in 35
cases, similar results were found in OSCC and other can-
cers [18,19,24,25], both peritumorally and intraumorally
which suggests that these vessels could be a conduit for
carcinoma cells and may contribute to lymph node
metastasis.
LVI was observed in 13 cases in the current study.
Other investigators reported similar findings in OSCC
and other cancers [19,24,25]. This may reflect a signifi-
cant role of these vessels in producing a possible route for
the spread of tumor cells to regional lymph nodes.
Fifteen cases showed D2-40 expression by tumor cells,
unfortunately there is no enough information concerning
D2-40 expression in OSCC, therefore it is difficult to
explain these results clearly. However, it may indicate a
more aggressive disease phenotype and suggest that D2-
40 may be implicated in the differentiation of SCC. Fur-
thermore, D2-40 positive tumor cells were detected in the
stromal tissue as well which suggests that it could act as a
good marker for microinvasion in OSCC, finding worth
more verification.
The current study showed no statistically significant
differences between EGFR expression median scores and
the clinicopatholgical findings; similar observations were
reported in other studies [4,17]. Furthermore, it was not
correlated with the other markers as well (except D2-40)
which indicate the independent effect of this marker on
epithelial cancers development and growth. Moreover,
the lack of correlation between EGFR extent or intensity
scores in respect to VEGF expression but its existence in
respect to LVD as shown in this study would favor lym-
phatic metastasis of OSCCs rather than hematogenous.
The results of the present study showed a statistically
significant difference regarding LVI with respect to the
median scores of ILVD, PLVD and TLVD. This finding
probably reflects the close relationship between LVI and
the lymphatic vessels since carcinomatous cells invade
the lymphatic vessels which exist in the area to get an
access to the regional lymph nodes. Furthermore, lack of
correlation between LVD, LVI and D2-40 positive tumor
cells may be attributed to the small size of node positive
cases (12 out of 40).
Among all the available studies reviewed, to the best of
our knowledge, the present work is the first of its kind in
studying comprehensively these biomarkers all together,
except several studies that assessed only two or three of
them together [15,21,26,27].
The results of this study clarify that the behavior of
OSCC is not dependent on a single factor but its combi-
nation of multiple biological processes which are inde-
pendent of each other i.e. malignancy follows no rules.
Table 3: The difference in median score of selected 
immunostains by lymphatic vessel invasion (Mann-
Whitney)
Lymphatic vessel invasion
Negative Positive P
Intratumoral LVD 0.002
Range (0 - 200) (24 - 160)
Median 17 45
Interquartile range (0 - 31) (32 - 64)
N2 2 1 3
Mean rank 13.82 25.08
Peritumoral LVD 0.026
Range (0 - 155) (9 - 240)
Median 42 72
Interquartile range (19 - 62) (48 - 120)
N2 2 1 3
Mean rank 15.05 23
Total LVD 0.004
Range (2 - 250) (54 - 300)
Median 52 115
Interquartile range (36 - 110) (91 - 200)
N2 2 1 3
Mean rank 14.18 24.46
LVD = Lymphatic vessel densitySarkis et al. Head & Neck Oncology 2010, 2:13
http://www.headandneckoncology.org/content/2/1/13
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